scholarly journals Impact of Fetal Weight in Assessment of Fetal Cardiac Output in Three Cases of High Output Cardiac Failure

2018 ◽  
Vol 3 (2) ◽  
pp. 83-86
Author(s):  
Behnaz Moradi ◽  
Mohammad Ali Kazem ◽  
Mahboobeh Shirazi ◽  
◽  
◽  
...  
2021 ◽  
Vol 17 ◽  
Author(s):  
Diane Xavier de Ávila ◽  
Humberto Villacorta ◽  
Wolney de Andrade Martins ◽  
Evandro Tinoco Mesquita

Introduction: The knowledge on high-output cardiac failure (HOCF) has greatly improved in the last two decades. One of the advances was the identification of a new phenotype of HOCF, characterized by absence of ventricular dilation, already associated with liver disease, arteriovenous fistulas (AVF), lung disease, myelodysplastic syndromes, and obesity. However, it has been noted that any aetiology can present with one of the two phenotypes, depending on the evolution. Objective: To describe, through an integrative review, the physiopathology and aetiologies of HOCF and to discuss phenotypes associated with this condition. Methods: Revisions, guidelines, case-controls, cohort studies and clinical studies were searched in MEDLINE and LILACS, using the connectives in the "cardiac output, high" database [MeSH Terms] OR "high cardiac output" [All Fields]. Discussion: Two distinct phenotypes are currently described in the HOCF, regardless of the aetiology: 1) one with enlarged cardiac chambers; and 2) with normal heart chambers. The mechanisms related to HOCF are vasodilation, arteriovenous shunts that cause increased microvascular density, reduced systemic vascular resistance (RSVR), and high metabolism. These mechanisms lead to activation of the renin-angiotensin-aldosterone system, sodium and water retention, activation of neprilysin, of the sodium-glucose-2 transporter, which promote interstitial fibrosis, ventricular remodeling and a consequent increase in cardiac output >8L/min. Conclusion: Many aetiologies of HOCF have been described and some of them are potentially curable. Prompt recognition of this condition and proper treatment may lead to better outcomes.


Author(s):  
R. Gourgon ◽  
J. P. Merillon ◽  
Y. Pansard ◽  
R. Prasquier ◽  
J. Y. Baglin ◽  
...  

2018 ◽  
Vol 71 (6) ◽  
pp. 896-903
Author(s):  
Amtul Aala ◽  
Sairah Sharif ◽  
Leslie Parikh ◽  
Paul C. Gordon ◽  
Susie L. Hu

PEDIATRICS ◽  
1972 ◽  
Vol 49 (4) ◽  
pp. 563-573
Author(s):  
Robert H. McLean ◽  
James H. Moller ◽  
Warren J. Warwick ◽  
Leon Satran ◽  
Russell V. Lucas

Multinodular hemangiomatosis of the liver (MHL) is characterized pathologically by multiple hemangiomas, primarily in the liver but also in other organs. The hepatic hemangiomas act as small arteriovenous fistulae and their combined effect may result in a massive peripheral arteriovenous shunt and high output congestive cardiac failure. Patients with MHL may be recognized clinically by the classical triad of congestive cardiac failure, hepatomegaly, and cutaneous hemangiomas. All but 2 of 31 cases of MHL herein reviewed had the onset of symptoms prior to 6 months of age. High output cardiac failure were severe and resulted in a 70% mortality. Hepatomegaly was massive and out of proportion to the degree of cardiac failure. Therapy includes intensive treatment of congestive cardiac failure and judicious transfusion in anemic patients. Irradiation of the liver and corticosteroids have been utilized in attempts to speed evolution of the hepatic arteriovenous fistulae. The data are not sufficient to establish the efficacy of either of these treatment modalities.


2004 ◽  
Vol 43 (5) ◽  
pp. e21.1-e21.6 ◽  
Author(s):  
Jennifer M MacRae ◽  
Sanjay Pandeya ◽  
Dennis P Humen ◽  
Nikolai Krivitski ◽  
Robert M Lindsay

2015 ◽  
Vol 09 (02) ◽  
pp. 227-232
Author(s):  
Reenu Malhotra ◽  
Luisa Florez ◽  
Dollett White ◽  
Sozos Papasozomenos ◽  
Michael Covinsky ◽  
...  

2013 ◽  
Vol 24 (4) ◽  
pp. 654-660 ◽  
Author(s):  
Stany Sandrio ◽  
Wolfgang Springer ◽  
Matthias Karck ◽  
Matthias Gorenflo ◽  
Alexander Weymann ◽  
...  

AbstractBackground: The aim of this study was to evaluate our experience in central extracorporeal life support with an integrated left ventricular vent in children with cardiac failure. Methods: Eight children acquired extracorporeal life support with a left ventricular vent, either after cardiac surgery (n = 4) or during an acute cardiac illness (n = 4). The ascending aorta and right atrium were cannulated. The left ventricular vent was inserted through the right superior pulmonary vein and connected to the venous line on the extracorporeal life support such that active left heart decompression was achieved. Results: No patient died while on support, seven patients were successfully weaned from it and one patient was transitioned to a biventricular assist device. The median length of support was 6 days (range 5–10 days). One patient died while in the hospital, despite successful weaning from extracorporeal life support. No intra-cardiac thrombus or embolic stroke was observed. No patient developed relevant intracranial bleeding resulting in neurological dysfunction during and after extracorporeal life support. Conclusions: In case of a low cardiac output and an insufficient inter-atrial shunt, additional left ventricular decompression via a vent could help avoid left heart distension and might promote myocardial recovery. In pulmonary dysfunction, separate blood gas analyses from the venous cannula and the left ventricular vent help detect possible coronary hypoxia when the left ventricle begins to recover. We recommend the use of central extracorporeal life support with an integrated left ventricular vent in children with intractable cardiac failure.


Sign in / Sign up

Export Citation Format

Share Document